Drug name
Paliperidone
Developer(s)
Drug information
Not provided
Paliperidone Palmitate
Not provided
Not provided
Paliperidone is an atypical antipsychotic drug indicated for the treatment of both schizophrenia & schizoaffective disorder. Paliperidone is the primary active metabolite of risperidone and functions by strongly binding to dopaminergic D2- and serotonergic 5-HT2-receptors and selectively blocking monoamine effects. Although paliperidone is a potent D2-antagonist, it has less of impact on motor function and catalepsy than traditional neuroleptics. Paliperidone palmitate is the palmitate ester prodrug of paliperidone and displays modest solubility in polar solvents. Several long-acting injectable aqueous nanocrystal formulations of paliperidone palmitate are available as once-monthly (PP1M), three-monthly (PP3M) and six-monthly (PP6M) extended-release suspensions for intramuscular injection.
Unknown
Unknown
Therapeutic area(s)
- Mental health
- Treatment
Administration route
Oral, Intramuscular
Associated long-acting platforms
Not provided
Use of drug
- Administered by a nurse
- Administered by a specialty health worker
- Self-administered
Not provided
Dosage
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Formulations
Compare
LY03010 (Paliperidone Palmitate Once-Monthly [PP1M])
Paliperidone Palmitate Once-Monthly (PP1M)
Paliperidone Palmitate Six-Monthly (PP6M)
Paliperidone Palmitate Three Monthly (PP3M)
Associated technologies
In-situ MicroimplantsComment & Information
Developer(s)
Janssen Pharmaceuticals is a subsidiary company of Johnson & Johnson headquartered in Beerse, Belgium. They focus on manufacturing and developing pharmaceutical products for use in areas such as, Immunology, Infectious Diseases & Vaccines, Pulmonary Hypertension, Cardiovascular & Metabolism, Oncology, and Neuroscience.
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients
Not provided
Not provided
Not provided
Delivery device(s)
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL
Publications
There are no publication
Additional documents
No documents were uploaded
Useful links
There are no additional links
Collaborate for development
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Share technical information for match-making assessment
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
Work with MPP to expand access in LMICs
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing